Survivin down-regulation by α-santalol is not mediated through PI3K-AKT pathway in human breast cancer cells

Anticancer Research

Volumn 35, Issue 10, 2015, Pages 5353-5358

  Bommareddy, Ajay ^a   Crisamore, Karryn ^a   Fillman, Sarah ^a   Brozena, Sarah ^a   Steigerwalt, James ^a   Landis, Terra ^a   VanWert, Adam L ^a   Dwivedi, Chandradhar ^b  

^a WILKES UNIVERSITY   (United States)

^b SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Caspase 3; PI3K AKT pathway; Survivin; santalol

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA SANTALOL; CASPASE 3; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SURVIVIN; TERPENOID; TRYPAN BLUE; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CHROMONE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; MORPHOLINE DERIVATIVE; SANTALOL; SESQUITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ELISA KIT; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MORPHOLINES; SESQUITERPENES;

EID: 84942776539     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics. CA Cancer J Clin 65: 5-29, 2015.
2. Bigler LR1, Streckfus CF, Copeland L, Burns R, Dai X, Kuhn M, Martin P and Bigler SA: The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med 31: 421-431, 2002.
3. Rivera E and Gomez H: Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 12: S2, 2010.
4. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
5. Lua PL, Salihah N and Mazlan N: Effects of inhaled ginger aromatherapy on chemotherapy-induced nausea and vomiting and health-related quality of life in women with breast cancer. Complement Ther Med 23: 396-404, 2015.
6. Dwivedi C, Valluri HB, Guan X and Agarwal R: Chemopreventive effects of alpha-santalol on ultraviolet B radiation-induced skin tumor development in SKH-1 hairless mice. Carcinogenesis. Carcinogenesis 27: 1917-1922, 2006.
7. Dwivedi C, Guan X, Harmsen WL, Voss AL, Goetz-Parten DE, Koopman EM, Johnson KM, Valluri HB and Matthees DP: Chemopreventive effects of alpha-santalol on skin tumor development in CD-1 and SENCAR mice. Cancer Epidemiol Biomarkers Prev 12: 151-156, 2003.
8. Arasada BL, Bommareddy A, Zhang X, Bremmon K and Dwivedi C: Effects of alpha-santalol on proapoptotic caspases and p53 expression in UVB-irradiated mouse skin. Anticancer Res 28: 129-132, 2008.
9. Bommareddy A, Hora J, Cornish B and Dwivedi C: Chemoprevention by alpha-santalol on UVB radiation-induced skin tumor development in mice. Anticancer Res 27: 2185-2188, 2007.
10. Santha S and Dwivedi C: Anticancer effects of sandalwood (Santalum album). Anticancer Res 35: 3137-3145, 2015.
11. Zhang X, Chen W, Guillermo R, Chandrasekher G, Kaushik RS, Young A, Fahmy H and Dwivedi C: Alpha-santalol, a chemopreventive agent against skin cancer, causes G2/M cell cycle arrest in both p53-mutated human epidermoid carcinoma A431 cells and p53 wild-type human melanoma UACC-62 cells. BMC Res Notes 3: 220, 2010.
12. Bommareddy A, Rule B, VanWert AL, Santha S and Dwivedi C: α-santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation. Phytomedicine 19: 804-811, 2012.
13. Saraswati S, Kumar S and Alhaider AA: α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer 12: 147, 2013.
14. Santha S, Bommareddy A, Rule B, Guillermo R, Kaushik RS, Young A and Dwivedi C: Antineoplastic effects of α-santalol on estrogen receptor-negative breast cancer cells through cell-cycle arrest at G2/M phase and induction of apoptosis. PLOS ONE 8: 1-12, 2013.
15. Kanwar JR, Kamalapuram SK and Kanwar RK: Survivin signaling in clinical oncology, a multifaceted dragon. Med Res Rev 33: 765-789, 2013.
16. Alteri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70, 2008.
17. Nabilis NH, Broaddus RR and Loose DS: DNA methylation inhibits p53-mediated survivin repression. Oncogene 28: 2046-2050, 2009.
18. Wang S, Huang X, Lee CK and Liu B: Elevated expression of ERBB3 confers paclitaxel resistance in ERBB2-overexpressing breast cancer cells via up-regulation of survivin. Oncogene 29: 4225-4236, 2010.
19. Zhu N, Gu L, Li F and Zhou M: Inhibition of the AKT/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther 7: 1101-1109, 2008.
20. Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcalá A, Chen YE, Njauw CN, Flaherty K, Jönsson G and Tsao H: Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res 19: 4383-4391, 2013.